Skye Bioscience, Inc.

Skye Bioscience, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing novel medicines by leveraging the pharmaceutical potential of the endocannabinoid system. The company's mission is to advance first-in-class molecules that modulate G-protein coupled receptors to address diseases characterized by inflammatory, fibrotic, and metabolic processes, with a particular emphasis on conditions with significant unmet medical needs.

Skye Bioscience's pipeline includes two primary product candidates: nimacimab and SBI-100 Ophthalmic Emulsion. Nimacimab is a peripherally restricted CB1-inhibiting antibody currently in Phase 2 clinical trials for the treatment of obesity and other metabolic diseases, being evaluated both as a monotherapy and in combination with GLP-1 receptor agonists. SBI-100 Ophthalmic Emulsion is a CB1 agonist in Phase 2 development for the treatment of glaucoma and ocular hypertension.

Recent developments for Skye Bioscience include the initiation of a higher-dose expansion study for nimacimab in April 2026 to inform Phase 2b dose selection for GLP-1 combination development. In March 2026, the company reported its fourth-quarter and full-year 2025 financial results. Earlier in 2026, Skye Bioscience announced a global collaboration and license agreement with Halozyme to evaluate nimacimab co-formulated with ENHANZE® for obesity. Punit Dhillon serves as the CEO, appointed in August 2020, and Paul Grayson was appointed Chairman of the Board in October 2024.